Postjunctional inhibitory effect of the NK2 receptor antagonist, SR 48968, on sensory NANC bronchoconstriction in the guinea-pig.
1 The effects of a selective NK2 receptor antagonist, SR 48968, on non-adrenergic non-cholinergic (NANC) bronchoconstriction in the guinea-pig were investigated in both in vitro and in vivo studies. 2 In isolated bronchus, the electrical field stimulation (EFS, 1 Hz for 1 min)-induced NANC bronchoconstriction was inhibited by 83% after preincubation with SR 48968 (10(-7) M) for 1 h. The selective NK1 receptor antagonist, CP 96,345 (10(-6) M), together with SR 48968 completely abolished the remaining EFS-evoked NANC bronchial contraction. ST 48968 (10(-7) M) totally blocked the bronchial contraction caused by neurokinin A (NKA), but reduced only slightly the bronchoconstriction caused by high concentrations of substance P (SP) and did not influence the response to acetylcholine (ACh). 3 In the guinea-pig isolated perfused lung, SR 48968 (5 x 10(-7) M) perfusion for 30 min markedly reduced, by 95% and 68% respectively, the increase in lung resistance (RL) and the decrease in dynamic compliance (CDyn) evoked by vagal stimulation (1 Hz for 1 min). Capsaicin (10(-8) M)-evoked bronchoconstriction was also significantly inhibited by SR 48968 (5 x 10(-7) M). However, the same concentration of SR 48968 did not affect the release of neuropeptide calcitonin gene-related peptide (CGRP)-like immunoreactivity (LI) evoked by either vagal stimulation or capsaicin in the isolated perfused lung, suggesting no prejunctional action. SR 48968 (5 x 10-7 M) caused a parallel shift of the concentration response curve to the right by a factor of 10 for the bronchoconstriction evoked by NKA(l0-9-3 x 10-7 M) in the isolated lung, while it abolished the contraction induced by the selective NK2 receptor agonist, Nle10 NKA(4-10) (10-9-3 x 10- 7 M).4. In in vivo studies, ST 48968 (0.3 mg kg-1, i.v.) also greatly inhibited the increase in insufflation pressure evoked by either capsaicin (10 microg kg-'1 i.v.) or NKA (1 microg kg-1, i.v.), without any measurable effect on the accompanying hypotensive responses.5. The results suggest: (i) ST 48968 is a selective and potent NK2 postjunctional receptor antagonist both in vitro and in vivo in the guinea-pig, and (ii) the NANC bronchoconstriction evoked by sensory nerve activation either by antidromic nerve stimulation or by capsaicin is mediated mainly via NK2 receptors and only to a minor extent via NK, receptors.
Department of Pharmacology, Karolinska Institute, Stockholm, Sweden.
Y P
YP
Lou
L Y
LY
Lee
H
H
Satoh
J M
JM
Lundberg
D000818:Animals; D001285:Atropine / Q000494:pharmacology; D001341:Autonomic Nervous System / Q000187:drug effects*; D001549:Benzamides / Q000494:pharmacology*; D016084:Bronchoconstriction / Q000187:drug effects*; D015740:Calcitonin Gene-Related Peptide / Q000276:immunology / Q000378:metabolism; D002211:Capsaicin / Q000037:antagonists & inhibitors / Q000494:pharmacology; D004558:Electric Stimulation; D005260:Female; D006168:Guinea Pigs; D066298:In Vitro Techniques; D008168:Lung / Q000187:drug effects / Q000378:metabolism; D008297:Male; D015288:Neurokinin A / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D009475:Neurons, Afferent / Q000187:drug effects / Q000378:metabolism; D009479:Neuropeptides / Q000378:metabolism; D010880:Piperidines / Q000494:pharmacology*; D017981:Receptors, Neurotransmitter / Q000037:antagonists & inhibitors*; D018039:Receptors, Tachykinin
D001549:Benzamides; D009479:Neuropeptides; D010880:Piperidines; D017981:Receptors, Neurotransmitter; D018039:Receptors, Tachykinin; C073839:SR 48968; D001285:Atropine; D015288:Neurokinin A; D015740:Calcitonin Gene-Related Peptide; D002211:Capsaicin